Skip to main content
Article thumbnail
Location of Repository

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

By J Smolen, R B Landewé, P Mease, J Brzezicki, D Mason, K Luijtens, R F van Vollenhoven, A Kavanaugh, M Schiff, G R Burmester, V Strand, J Vencovský and D van der Heijde
Topics: Clinical and Epidemiological Research
Publisher: BMJ Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2674556
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
    2. (1999). A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    3. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum
    4. (1995). American College of Rheumatology. Preliminary definition of improvementi n rheumatoid arthritis. Arthritis Rheum
    5. Certolizumab pegol for the treatment of Crohn’s disease.
    6. (2008). Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum
    7. (2007). Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol
    8. (2002). Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology
    9. (2007). Expert agreement confirms that negative changes in hand and foot radiographs are as u r r o g a t e for repair in patients with rheumatoid arthritis. Arthritis Res Ther
    10. (1999). How to read radiographs according to the Sharp/van der Heijde method.
    11. (2002). How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum
    12. Improved health-related quality of life with effective diseasemodifying antirheumatic drugs: evidence from randomized controlled trials.
    13. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.
    14. Infliximab and methotrexate in the treatment of rheumatoid arthritis.
    15. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376–92. Extended report 804 Ann Rheum Dis 2009;68:797–804. doi:10.1136/ard.2008.101659
    16. (1999). Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum
    17. Maintenance therapy with certolizumab pegol for Crohn’s disease.
    18. (2006). Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum
    19. (2007). Mechanism of action of certolizumab pegol (CDP970): in vitro comparison with other anti-tumor necrosis factor a agents. Inflamm Bowel Dis
    20. (1993). Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective.
    21. (1995). Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev
    22. (2008). Organization. WHO country data: estimated burden of TB. Available at http://www.hpa.org.uk/infections/topics_az/tb/epidemiology/who_table1.htm (accessed 18
    23. (2006). Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum
    24. (1987). revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum
    25. (2003). Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum
    26. (1996). Role of cytokines in rheumatoid arthritis. Ann Rev Immunol
    27. (2003). Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology
    28. (2001). SF-36 Physical and Mental Health Summary Scales: manual for users version 1. 2nd ed.
    29. (1996). Statistical considerations for multiplicity in confirmatory protocols.
    30. (2001). The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum
    31. (2002). The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum
    32. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.
    33. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
    34. (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) blocking agents and interleukin-1 receptor antagonist (IL-1RA), for the treatment of rheumatic diseases,
    35. (2000). Use of targeted anticytokine treatments in heart failure. Circulation

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.